GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gubra AS (OCSE:GUBRA) » Definitions » Capex-to-Revenue

Gubra AS (OCSE:GUBRA) Capex-to-Revenue : 0.07 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Gubra AS Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Gubra AS's Capital Expenditure for the six months ended in Dec. 2023 was kr-7.37 Mil. Its Revenue for the six months ended in Dec. 2023 was kr103.19 Mil.

Hence, Gubra AS's Capex-to-Revenue for the six months ended in Dec. 2023 was 0.07.


Gubra AS Capex-to-Revenue Historical Data

The historical data trend for Gubra AS's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gubra AS Capex-to-Revenue Chart

Gubra AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
- 0.04 0.11 0.07 0.06

Gubra AS Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial - 0.07 0.07 0.04 0.07

Competitive Comparison of Gubra AS's Capex-to-Revenue

For the Biotechnology subindustry, Gubra AS's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gubra AS's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gubra AS's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Gubra AS's Capex-to-Revenue falls into.



Gubra AS Capex-to-Revenue Calculation

Gubra AS's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-11.196) / 205.005
=0.05

Gubra AS's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-7.365) / 103.188
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gubra AS  (OCSE:GUBRA) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Gubra AS Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Gubra AS's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Gubra AS (OCSE:GUBRA) Business Description

Traded in Other Exchanges
Address
Hørsholm Kongevej 11B, Hørsholm, DNK, 2970
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases.

Gubra AS (OCSE:GUBRA) Headlines

No Headlines